Table I. Demographic data of study participants
HIV Patients Recruited in Perth, Australia (n = 34)SCOPE (n = 89)
Controller (n = 14)Noncontroller (n = 20)Elite Controller (n = 30)Viremic Controller (n = 29)Noncontroller (n = 30)
CD4+ T cell counta (cells/μl blood)672b (504–1302)58 (4–196)1029c (363–2199)519 (359–988)466 (356–1287)
HIV-1 viral loada (copies/ml blood)40 (40–513)120,534 (6,310–602,560)<75d313 (75–1658)52,850 (10,619–334,034)
Gender (Male/female/transgender/intersex)7/7/0/017/3/0/018/11/1/024/3/2/025/2/2/1
Agea43 (23–65)49 (25–67)50e (32–77)49 (28–60)46 (27–71)
  • a The data are presented as median (range).

  • b CD4+ T cell counts are significantly higher than noncontrollers of the Perth cohort (p < 0.0001).

  • c CD4+ T cell counts are significantly higher than viremic controllers (p = 0.0001) and noncontrollers of the SCOPE cohort (p < 0.0001).

  • d Viral loads shown here are below the limit of detection as assessed by different diagnostic platforms (Roche COBAS AmpliPrep/COBAS TaqMan > 20, Abbott real-time HIV-1 PCR > 40, Roche PCR > 50, branched DNA > 75).

  • e Age significantly higher than noncontrollers of the SCOPE cohort (p = 0.03).